dual glp-1/glucagon receptor agonists Discovery of Biased Dual-Agonists of Glucagon-Like Peptide 1 and Glucagon Receptors through Mutation of a Conserved Aspartate Machine learning designs new GCGR/GLP-1R
Description
A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro

Aims/hypothesis Unimolecular peptides targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG) have been shown to improve glycaemic management in both mice and humans

Scientists have now created long-lasting GLP-1 drugs that can be used to treat type 2 diabetes, obesity, and a range of other conditions

Recent research suggests that semaglutide, a medication primarily used for type 2 diabetes and weight management, may also help reduce alcohol consumption

Obesity is a chronic disease associated with many complications
